Your Search Returned 118 tagged news reports
TPI 287 is a new taxoid derivative, called as an abeotaxane, which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol and Abraxane) and docetaxel (Taxotere). It has distinct advantages
The company also intends to submit marketing authorization application for the drug to the European Medicines Agency (EMA) later in 2014...The trail was carried out at sites in the US, Canada, Europe, Australia, Russia, Israel and Asian countries
S Published 10 March 2014 Teva Pharmaceutical Industries has launched the generic equivalent to Xeloda (capecitabine) tablets, 150mg and 500mg, in the US...Teva claims that it was the first to receive approval on its abbreviated new drug application
Eli Lilly and Co said its experimental lung cancer drug significantly improved patient survival rates compared to a placebo in a late-stage trial. The trial also showed that the drug, ramucirumab, improved survival rates without the cancer worsening.
Quebec public drug formulary for treatment earlier in advanced disease."
Alfred Hospital, while 1 to 2 additional sites are expected to be added in the near future. About 30 patients with solid tumours will be enrolled in the trial, whose primary objective is to establish the maximum tolerated dose (MTD) and dose limiting
Overall, investors, companies, and patients have seen some major advances in the oncology space...The deal Bayer and Norwegian biotech Algeta announced on Thursday morning that the two companies agreed to a proposal whereby Bayer will acquire the
The independent Data and Safety Monitoring Committee overseeing the trial recommended to the National Cancer Institute (NCI), part of NIH, that the study results be made public because a recent planned interim analysis showed prolongation in overall
Sitka Biopharma is a biotechnology company developing a new bladder cancer treatment. Sitka's technology combines a nanoparticulate drug delivery technology based on hyperbranched polyglycerols (HPG), with docetaxel, a well characterized
The trial is the second of three Phase Ib trials for vantictumab that the company intends to start in 2013 as part of its collaboration with Bayer Pharma. Primary objectives of the Phase 1b clinical trial are to assess safety of the combination